Lifecore Biomedical, Inc. (LFCR)
| Market Cap | 154.44M -45.2% |
| Revenue (ttm) | 129.46M +0.8% |
| Net Income | -34.50M |
| EPS | -0.93 |
| Shares Out | 37.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 208,115 |
| Open | 4.290 |
| Previous Close | 4.310 |
| Day's Range | 4.060 - 4.310 |
| 52-Week Range | 3.625 - 8.980 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 6.75 (+65.44%) |
| Earnings Date | Aug 5, 2026 |
About LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk... [Read more]
Financial Performance
In 2025, Lifecore Biomedical's revenue was $129.46 million, an increase of 0.46% compared to the previous year's $128.87 million. Losses were -$34.50 million, -22.22% less than in 2025.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for LFCR stock is "Buy." The 12-month stock price target is $6.75, which is an increase of 65.44% from the latest price.
News
Lifecore Biomedical to Participate at CPHI Global Conference
CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore signs agreement for commercial site transfer for pharmaceutical company
Lifecore (LFCR) announced it has signed a new agreement to transfer a commercially marketed product to the company’s pipeline. Under the terms of the agreement, Lifecore will perform technical transfe...
Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company
-- Significant New Program Positioned to Become One of Lifecore's Largest Contracts -- -- Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Drug Product -- -- Program...
Lifecore price target lowered to $6.25 from $6.50 at Barrington
Barrington analyst Michael Petusky lowered the firm’s price target on Lifecore (LFCR) to $6.25 from $6.50 and keeps an Outperform rating on the shares. The firm views the company’s Q2…
Lifecore Biomedical Earnings Call Transcript: Q2 2026
Q2 revenue and profit declined year-over-year, but cost reductions and new business wins support reaffirmed 2026 guidance. Strong HA manufacturing and CDMO momentum, combined with industry tailwinds and operational improvements, position the company for mid- and long-term growth.
Lifecore Biomedical Earnings release: Q2 2026
Lifecore Biomedical released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Lifecore Biomedical Quarterly report: Q2 2026
Lifecore Biomedical has published its Q2 2026 quarterly earnings report on August 5, 2026.
Lifecore Biomedical Slides: Q2 2026
Lifecore Biomedical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update
-- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -- -- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization -- Conference ...
Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026
CHASKA, Minn., July 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore signs three new customer agreements
Lifecore (LFCR) announced it has signed three new customer agreements, further expanding its pipeline of early- and late-stage programs. The three agreements span multiple therapeutic and technology a...
Lifecore Biomedical Signs Three New Customer Agreements
--Technology Transfer Agreement for Regenerative Medicine Late-Stage Development Program-- --Two Additional Agreements Supporting Early-Stage Programs Including Formulation and Development for a Globa...
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHASKA, Minn., July 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), toda...
Lifecore price target raised to $6.50 from $6 at Barrington
Barrington raised the firm’s price target on Lifecore (LFCR) to $6.50 from $6 and keeps an Outperform rating on the shares after the company said it signed a new agreement…
Lifecore signs agreement with global pharmaceutical company
Lifecore (LFCR) announced it has signed a new agreement with a global pharmaceutical company. Under the terms of the agreement, Lifecore will perform technical transfer services to support the commerc...
Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product-- --Seventh Addition to Lifecore's Late-Stage Pipeline in Seven Months-- CHASKA, Minn., June 15,...
Lifecore Biomedical Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and a new stock incentive plan, all of which were approved by shareholders. No questions were raised, and final voting results will be filed with the SEC.
Lifecore signs manufacturing pact with ophthalmic disease management provider
Lifecore (LFCR) announced that it has signed a manufacturing services agreement with a provider of ophthalmic disease management solutions. Under the terms of the agreement, Lifecore will perform proc...
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product -- -- Sixth Addition to Late-Stage Pipeline in Seven Months -- CHASKA, Minn....
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference
CHASKA, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), toda...
Lifecore Biomedical to Participate at CDMO Live Europe
CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore reports Q1 EPS (43c), consensus (29c)
Reports Q1 revenue $23.19M, consensus $25.96M. “During the first quarter, Lifecore (LFCR) continued to successfully execute the three pillars of its growth strategy – maximizing our existing commercia...
Lifecore Biomedical Earnings Call Transcript: Q1 2026
Q1 2026 saw a 34% revenue decline year-over-year, but cost reductions and new business wins support reaffirmed 2026 guidance. Strong pipeline growth, especially in prefilled syringes, and positive cash flow position the company for a stronger second half.
Lifecore Biomedical Earnings release: Q1 2026
Lifecore Biomedical released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Lifecore Biomedical Quarterly report: Q1 2026
Lifecore Biomedical has published its Q1 2026 quarterly earnings report on May 6, 2026.